Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is gestational trophoblastic disease?
Gestational trophoblastic disease (GTD) is a rare group of conditions in which abnormal cells grow from the trophoblast — the tissue that would normally form the placenta during pregnancy. It can begin after any kind of pregnancy, including a normal pregnancy, a miscarriage, or a molar pregnancy (a pregnancy in which the placental tissue grows abnormally and no healthy baby develops). Most GTD is not cancerous and is called a hydatidiform mole, but in some cases it becomes a true tumor that can grow into the wall of the uterus or spread elsewhere — this cancerous form is called gestational trophoblastic neoplasia (GTN). Common signs include unusual vaginal bleeding after a pregnancy or miscarriage, a uterus that is larger than expected, or severe nausea. Doctors monitor GTD using a simple blood test for the pregnancy hormone hCG, which these tumors produce; a rising or stubbornly high hCG level signals that treatment is needed. The encouraging news is that GTN is among the most curable of all cancers — it responds extremely well to chemotherapy, and the great majority of women are cured and can still have healthy pregnancies later.
The main types
Doctors group gestational trophoblastic disease by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Hydatidiform mole (molar pregnancy) | The most common, usually non-cancerous form, where placental tissue grows abnormally; most are cured simply by removing the tissue from the uterus, with hCG monitoring afterward. |
| Invasive mole | A mole that grows into the muscular wall of the uterus; it can cause bleeding and usually needs chemotherapy. |
| Choriocarcinoma | A fast-growing cancer of trophoblast cells that can spread to the lungs, brain, or other organs; despite this, it is highly curable with chemotherapy. |
| Placental-site and epithelioid trophoblastic tumor | Rare forms that grow where the placenta was attached; these respond less to chemotherapy, so surgery often plays a larger role. |
Staging, in plain terms
Gestational trophoblastic neoplasia uses its own system rather than the TNM system used for most cancers. It combines a FIGO anatomic stage (I through IV, describing whether the tumor is confined to the uterus or has spread to the pelvis, lungs, or distant organs such as the brain) with a separate WHO/FIGO risk score. The risk score adds up points for factors such as age, the type of pregnancy that came before, how high the hCG level is, tumor size, where it has spread, and whether earlier chemotherapy has been tried. A low score (low-risk disease) is usually cured with a single chemotherapy drug, while a higher score (high-risk disease) is treated with a combination of drugs. This careful scoring is a big reason cure rates are so high.
| FIGO anatomic stage I–IV plus a WHO/FIGO risk score (not TNM) | What it generally means |
|---|---|
| Stage I | The tumor is confined to the uterus. |
| Stage II | The tumor has extended outside the uterus to nearby structures in the pelvis, such as the vagina. |
| Stage III | The tumor has spread to the lungs — the most common site of spread — with or without involvement of the genital tract. |
| Stage IV | The tumor has spread to other distant organs, such as the brain, liver, kidneys, or digestive tract. |
The standard of care
Gestational Trophoblastic Disease is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Surgery to remove the mole (D&C)
For a molar pregnancy, gently removing the abnormal tissue from the uterus (a procedure called dilation and curettage) is usually the first step, followed by hCG monitoring.
Single-drug chemotherapy
Low-risk GTN is cured in the vast majority of women with one chemotherapy medicine, most often methotrexate or actinomycin-D.
Combination chemotherapy
High-risk GTN is treated with a combination of drugs (such as the EMA-CO regimen), which cures most women even when the cancer has spread.
hCG monitoring
The pregnancy hormone hCG is followed with regular blood tests to confirm the disease is gone and to catch any return early; women are advised to avoid pregnancy during monitoring.
Hysterectomy (in selected cases)
Removing the uterus is an option for women who do not wish to preserve fertility, or for the rarer placental-site and epithelioid tumors that respond less to chemotherapy.
How radiation treatment works
Radiation uses focused high-energy beams to damage the DNA inside cancer cells so they can no longer grow and divide. For gestational trophoblastic disease, chemotherapy — not radiation — is the main treatment, because these tumors are remarkably sensitive to chemotherapy and most women are cured without ever needing radiation. Radiation has a specific, limited role: it is used mainly when choriocarcinoma has spread to the brain, where radiation alongside chemotherapy helps control the disease and reduce the risk of dangerous bleeding. It can also occasionally help control bleeding or treat a stubborn deposit of tumor in one location. When radiation is used, it is planned carefully to focus on the target and protect healthy tissue, and treatments themselves are quick and painless. Your care team will explain whether radiation has any role in your specific situation; for the large majority of women with this disease, it does not.
The main ways radiation is delivered for gestational trophoblastic disease:
Whole-brain radiation
When choriocarcinoma spreads to the brain, radiation to the whole brain may be added alongside chemotherapy to control disease and prevent bleeding, helping achieve cure even in advanced cases.
Targeted (stereotactic) radiation
For a small number of brain spots, focused stereotactic radiation can treat the area precisely while sparing surrounding healthy brain.
Radiation for local control
Rarely, radiation is used to control bleeding or treat a stubborn deposit of tumor in a specific spot when chemotherapy and surgery are not enough.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
Cure with fertility preserved: Decades of experience show that even high-risk gestational trophoblastic neoplasia is cured in the great majority of women with chemotherapy, and most are able to have healthy pregnancies afterward.[1]
International GTN treatment registries and FIGO guidance
Immunotherapy for resistant disease: For the rare cases that resist standard chemotherapy, immune-checkpoint drugs such as pembrolizumab have produced durable remissions, offering a new option that may sometimes spare more intensive treatment.[2]
Trophoblastic tumor immunotherapy studies
Refining who needs combination chemotherapy: Research continues to fine-tune the risk score so that low-risk women receive the gentlest effective single-drug treatment while high-risk women get combination therapy promptly, keeping cure rates near-universal.[3]
WHO/FIGO risk-scoring outcome analyses
Common questions
Is gestational trophoblastic disease curable? Yes — it is one of the most curable of all cancers. Most molar pregnancies are cured by removing the tissue, and even the cancerous form (gestational trophoblastic neoplasia), including cases that have spread, is cured in the great majority of women with chemotherapy.
Will I be able to have children afterward? Usually, yes. Most treatment preserves the uterus, and the large majority of women go on to have normal, healthy pregnancies. Your team will ask you to avoid pregnancy during the hCG monitoring period so your blood tests stay easy to interpret.
Will I need radiation? Most women do not. Chemotherapy is the main treatment because these tumors are so sensitive to it. Radiation is reserved for specific situations, mainly when the cancer has spread to the brain, and your team will tell you if it applies to you.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.